Haimai Medical
Tissue-engineered blood vessels for cardiovascular surgeries.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
N/A | Series A | ||
| Total Funding | 000k | ||
Haimai Medical, also known as Humatrix Medical Technology (Suzhou) Co., Ltd., is a company focused on regenerative medicine and tissue engineering for cardiovascular disease treatment. Founded in 2021 and based in Suzhou, China, the firm develops and provides tissue-engineered technologies for surgical applications.
The company's core products are allogeneic, small-caliber tissue-engineered blood vessels. These are designed for various procedures, including creating vascular access for chronic renal failure dialysis, replacing blood vessels after lower extremity arterial trauma, and for surgeries related to lower extremity atherosclerosis and coronary heart disease bypass. The technology aims to create a nanostructured, low-immunogenic biological artificial blood vessel that can be rapidly recellularized by the patient's own cells after implantation, effectively reconstructing a new vessel in-situ. This process is intended to overcome common issues with artificial grafts like calcification and immune rejection, thereby improving long-term durability and patency rates.
Haimai Medical operates as a privately held, series A company. It secured an undisclosed amount in a Series A funding round in August 2024, with investors including IDG Capital and Huafang Capital.
Keywords: tissue engineering, regenerative medicine, cardiovascular diseases, tissue-engineered blood vessels, allogeneic grafts, vascular access, bypass surgery, atherosclerosis treatment, arterial trauma repair, nanostructured biomaterials, recellularization, surgical devices, medical technology, Suzhou biotech